Income Statement
CENTESSA PHARMACEUTICALS PLC
CNTA
Performance Overview
Click any row in the table to add it to this chart
in millions USD
| Metric | Dec 31, 2025 2025 FY | Dec 31, 2024 2024 FY | Dec 31, 2023 2023 FY | Dec 31, 2022 2022 FY | Dec 31, 2021 2021 FY |
|---|---|---|---|---|---|
|
Revenue
|
15.00 | 0.00 | 6.85 | - | - |
|
Cost of Revenue
|
- | - | - | - | - |
|
Gross Profit
|
15.00 | - | 6.85 | - | - |
|
Operating Expenses
|
50.47 | 50.81 | 53.73 | 55.20 | 42.89 |
|
Research & Development
|
172.22 | 150.24 | 124.41 | 155.08 | 95.66 |
|
Selling, General & Administrative
|
50.47 | 50.81 | 53.73 | 55.20 | 42.89 |
|
Other Operating Expenses
|
- | - | - | - | - |
|
Operating Income
|
-35.47 | -50.81 | -46.88 | -55.20 | -42.89 |
|
Non-Operating Income
|
160.25 | 182.10 | 129.26 | 161.75 | 338.07 |
|
Interest Income
|
20.53 | 14.02 | - | - | - |
|
Interest Expense
|
- | - | 9.91 | - | - |
|
Other Non-Op Income / Expense
|
2.91 | -1.69 | -5.43 | 2.34 | -4.37 |
|
Income Before Tax
|
-195.71 | -232.91 | -176.14 | -216.95 | -380.96 |
|
Income Tax Expense
|
1.82 | 2.84 | -25.06 | -0.75 | 0.11 |
|
Non-Controlling Interest
|
- | - | - | - | - |
|
Net Income
|
-197.53 | -235.76 | -151.09 | -216.21 | -381.07 |
Supplemental
Per share data, derived & other items — not part of the income statement
in millions USD unless noted
| Metric | Dec 31, 2025 2025 FY | Dec 31, 2024 2024 FY | Dec 31, 2023 2023 FY | Dec 31, 2022 2022 FY | Dec 31, 2021 2021 FY |
|---|---|---|---|---|---|
|
Depreciation & Amortization
|
- | - | - | - | - |
|
EBITDA
|
-34.55 | -49.87 | -46.07 | -55.07 | -42.85 |
|
Earnings Per Share (Basic)
|
-1.46 | -2.06 | -1.57 | -2.31 | -5.07 |
|
Diluted EPS
|
-1.46 | -2.06 | -1.57 | -2.31 | -5.07 |
|
Weighted Average Shares
|
135.72 | 114.47 | 96.18 | 93.40 | 75.17 |
|
Diluted Weighted Avg Shares
|
135.72 | 114.47 | 96.18 | 93.40 | 75.17 |
|
Comprehensive Income
|
-199.03 | -233.04 | -148.10 | -218.39 | -380.29 |